KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Moderna (MRNA) over the last 10 years, with Q3 2025 value amounting to $1.1 billion.

  • Moderna's Cash & Equivalents fell 3114.36% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 3114.36%. This contributed to the annual value of $1.9 billion for FY2024, which is 3371.17% down from last year.
  • Latest data reveals that Moderna reported Cash & Equivalents of $1.1 billion as of Q3 2025, which was down 3114.36% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Moderna's Cash & Equivalents peaked at $6.8 billion during Q4 2021, and registered a low of $1.1 billion during Q3 2025.
  • Over the past 5 years, Moderna's median Cash & Equivalents value was $2.9 billion (recorded in 2023), while the average stood at $3.3 billion.
  • In the last 5 years, Moderna's Cash & Equivalents surged by 128826.53% in 2021 and then plummeted by 5319.8% in 2022.
  • Quarter analysis of 5 years shows Moderna's Cash & Equivalents stood at $6.8 billion in 2021, then plummeted by 53.2% to $3.2 billion in 2022, then fell by 9.3% to $2.9 billion in 2023, then tumbled by 33.71% to $1.9 billion in 2024, then plummeted by 41.26% to $1.1 billion in 2025.
  • Its Cash & Equivalents stands at $1.1 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.6 billion for Q1 2025.